Johnson & Johnson (J&J) announced that it’s pulling the plug on atopic dermatitis trials for the drug bermekimab, a move that is costing the company $610 million. Source: Drug Industry…
In an effort to better understand high prices for drugs and diagnostics, a group of doctors has called on the Biden administration to openly share the costs of clinical trials…
ViiV Healthcare’s Apretude (cabotegravir), a recently approved long-acting injectable for preventing HIV in adults and adolescents, isn’t cost-effective despite offering new hope against the deadly disease, a new analysis contends.…
Continuing resolution (CR) funding for the FDA at fiscal 2021 levels denies the FDA increased funding as Congress intended, limits new program starts and makes it difficult for the agency…
Drug wholesalers McKesson, AmerisourceBergen and Cardinal Health, and the Janssen subsidiary of Johnson & Johnson (J&J) have agreed to pay a combined $590 million to settle lawsuits with Native American…
Gilead Sciences will pay GlaxoSmithKline (GSK) $1.25 billion plus royalties to end a four-year-old patent fight between Gilead and human immunodeficiency virus (HIV)-focused ViiV Healthcare, a company launched in 2009…
The FDA has approved the first-ever generic of AbbVie’s 20-year-old immunomodulator Restasis for dry eye — Mylan Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05 percent single-use vials. Source: Drug Industry Daily
The University of Pennsylvania is suing Genentech for patent infringement of four pharmacologically related breast cancer chemotherapy agents, alleging that the drugs were originally created by university researchers and fully…
Gilead Sciences will pay GlaxoSmithKline (GSK) $1.25 billion plus royalties to end a four-year-old patent fight between Gilead and human immunodeficiency virus (HIV)-focused ViiV Healthcare, a company launched in 2009…
It sure appears as though Robert Califf’s second confirmation as FDA commissioner could be in jeopardy. Source: Drug Industry Daily